KR890016968A - 약제 흡착물 - Google Patents
약제 흡착물 Download PDFInfo
- Publication number
- KR890016968A KR890016968A KR1019890006425A KR890006425A KR890016968A KR 890016968 A KR890016968 A KR 890016968A KR 1019890006425 A KR1019890006425 A KR 1019890006425A KR 890006425 A KR890006425 A KR 890006425A KR 890016968 A KR890016968 A KR 890016968A
- Authority
- KR
- South Korea
- Prior art keywords
- ranitidine
- resinous
- adsorbate
- pharmaceutical composition
- cation exchange
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (20)
- 라니티딘과 합성 양이온 교환 수지사이에 형성된 화합물로 되는 수지성 흡착물.
- 제 1 항에 있어서, 양이온 교환 수지가 스티렌, 아크릴산 또는 메타크릴산과 방향족 비닐 화합물과의 공중합체이고, 수지 유도체가 약산 또는 강산 기로부터 수지의 교환 활성도를 유도하는 것을 특징으로 하는 수지성 흡착물.
- 제 2 항에 있어서, 합성 양이온 교환 수지가 스티렌 및 술폰화 디비닐벤젠의 공중합체이거나 또는 메타크릴산 및 디비닐벤젠의 공중합체인 것을 특징으로 하는 수지성 흡착물.
- 제2 또는 3항에서 있어서, 합성 양이온 교환 수지가 산형태 또는 알칼리 금속과 함께 염형태인 것을 특징으로 하는 수지성 흡착물.
- 제 1 항에 있어서, 합성 양이온 교환 수지가 유리산 형태중의 메타크릴산 디비닐벤젠 수지인 것을 특징으로 하는 수지성 흡착물.
- 제1 내지 5항중 어느 1개 항에 있어서, 수지성 흡착물의 중량에 기초해서 라니티딘 유리 염기의 중량으로 나타낸 5 내지 70%의 라니티딘을 함유하는 것을 특징으로 하는 수지성 흡착물.
- 제 6 항에 있어서, 20 내지 30%의 라니티딘을 함유하는 것을 특징으로 하는 수지성 흡착물.
- 제1 내지 7항중 어느 1개 항에 있어서, 합성 양이온 교환 수지와 라니티딘 또는 생리학적으로 허용가능한 그의 염을 접촉시키는 것으로 되는 수지성 흡착물의 제조 방법.
- 제 8 항에 있어서, 합성 양이온 교환 수지가 라니티딘 또는 라니티딘 히드로클로라이드와 접촉되는 것을 특징으로 하는 수지성 흡착물의 제조 방법.
- 제 8 항에 있어서, 라니티딘 유리 염기가 유리산 형태의 메타크릴산 디비닐벤젠 수지와 접촉되는 것을 특징으로 하는 수지성 흡착물의 제조 방법.
- 제1 내지 7항중 어느 1개 항에 있어서, 수지성 흡착물이 약학적으로 허용가능한 적어도 1종의 담체 또는 부형제와 함께 구성된 경구 투여용 약학 조성물.
- 제11항에 있어서, 씹거나 빨아먹을 수 있는 정제형태의 약학 조성물.
- 제11항에 있어서, 과립제 형태인 약학 조성물.
- 제11항에 있어서, 수용성 현탁액제 형태인 약학 조성물.
- 제11항에 있어서, 비수용성 현탁액제 형태인 약학 조성물.
- 제1 내지 7항중 어느 1개 항에 있어서, 수지성 흡착물이 약학적으로 허용가능한 적어도 1종의 담체 또는 부형제와 함께 구성되고 사용 전에 수용상 비히클로 재구성시킬수 있게 한 건조 생성물로 되는 약학 조성물.
- 약학적으로 허용가능한 적어도 1종의 담체 또는 부형제와 함께 라니티딘 또는 생리학적으로 허용가능한 그의 염과 합성 양이온 교환 수지고 되고, 후에 수용성 비히클 중에 제 1 항의 정의한 바와 같은 수지성 흡착물을 형성하는 건조 생성물 형태의 경구 투여용 약학 조성물.
- 제17항에 있어서, 라니티딘 또는 라니티딘 히드로클로라이드와 제2 내지 5항중 어느 1개 항에서 정의한 바와 같은 합성 양이온 교환 수지를 함유하는 약학 조성물.
- 제11 내지 18항중 어느 1개 항에 있어서, 라니티딘 유리 염기의 중량으로 나타낸 1회 투여량 단위 당 라니티딘 50 내지 600mg을 함유하는 1회 단위 투여량의 약학 조성물.
- 제19항에 있어서, 단위 투여량 당 라니티딘 50 내지 400mg을 함유하는 약학 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888811167A GB8811167D0 (en) | 1988-05-11 | 1988-05-11 | Medicaments |
GB8811167.9 | 1988-05-11 | ||
GB8816185 | 1988-07-07 | ||
GB888816185A GB8816185D0 (en) | 1988-07-07 | 1988-07-07 | Medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
KR890016968A true KR890016968A (ko) | 1989-12-14 |
Family
ID=26293879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890006425A KR890016968A (ko) | 1988-05-11 | 1989-05-10 | 약제 흡착물 |
Country Status (35)
Country | Link |
---|---|
US (1) | US5032393A (ko) |
JP (1) | JP2944678B2 (ko) |
KR (1) | KR890016968A (ko) |
CN (1) | CN1027133C (ko) |
AT (1) | AT401614B (ko) |
AU (1) | AU624613B2 (ko) |
BE (1) | BE1002159A5 (ko) |
CA (1) | CA1337272C (ko) |
CH (1) | CH679011A5 (ko) |
CY (1) | CY1781A (ko) |
DE (1) | DE3915347C2 (ko) |
DK (1) | DK168934B1 (ko) |
ES (1) | ES2011573A6 (ko) |
FI (1) | FI92060C (ko) |
FR (1) | FR2631232B1 (ko) |
GB (1) | GB2218333B (ko) |
GR (1) | GR1000358B (ko) |
HK (1) | HK45094A (ko) |
HU (2) | HU204994B (ko) |
IE (1) | IE60722B1 (ko) |
IL (1) | IL90245A (ko) |
IT (1) | IT1232831B (ko) |
LU (1) | LU87515A1 (ko) |
MX (1) | MX173349B (ko) |
MY (1) | MY104013A (ko) |
NL (1) | NL8901188A (ko) |
NO (1) | NO175131C (ko) |
NZ (1) | NZ229064A (ko) |
PH (1) | PH27612A (ko) |
PL (1) | PL279377A1 (ko) |
PT (1) | PT90523B (ko) |
RU (1) | RU2033155C1 (ko) |
SE (1) | SE508343C2 (ko) |
SG (1) | SG48194G (ko) |
YU (1) | YU47674B (ko) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219563A (en) * | 1988-05-11 | 1993-06-15 | Glaxo Group Limited | Drug adsorbates |
CA2002492A1 (en) * | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
GB8904182D0 (en) * | 1989-02-23 | 1989-04-05 | Glaxo Canada | Pharmaceutical compositions |
SE9003902D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | Solid dosage forms of a drug |
GB8925484D0 (en) * | 1989-11-10 | 1989-12-28 | Glaxo Group Ltd | Process |
AU8546591A (en) * | 1990-09-13 | 1992-04-15 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
SE9003903D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | New pharmaceutical formulations |
JPH06504059A (ja) * | 1990-12-21 | 1994-05-12 | リチャードソン、ビックス、インコーポレーテッド | ポリアミン薬物−樹脂複合体 |
US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
JP3207494B2 (ja) * | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | 水性懸濁製剤 |
JP3278192B2 (ja) * | 1992-04-03 | 2002-04-30 | ロート製薬株式会社 | 徐放性液剤 |
GB9211148D0 (en) * | 1992-05-26 | 1992-07-08 | Smithkline Beecham Plc | Novel treatment |
GB9221414D0 (en) * | 1992-10-13 | 1992-11-25 | Glaxo Group Ltd | Pharmaceutical compositions |
WO1994008576A1 (en) * | 1992-10-16 | 1994-04-28 | Glaxo Group Limited | Taste-masking compositions of ranitidine |
EP0620001A1 (en) * | 1993-04-16 | 1994-10-19 | McNEIL-PPC, INC. | Aqueous pharmaceutical suspension and process for preparation thereof |
GB9324409D0 (en) * | 1993-11-27 | 1994-01-12 | Smithkline Beecham Plc | Novel composition |
US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
JP4283355B2 (ja) * | 1997-11-10 | 2009-06-24 | 久光製薬株式会社 | 薬剤用徐放化剤及びそれを含有した徐放性医薬組成物 |
CA2309597A1 (en) | 1997-11-10 | 1999-05-20 | Hiroshi Sorimachi | Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same |
ATE411047T1 (de) * | 1999-07-14 | 2008-10-15 | Schering Plough Ltd | Maskieren des geschmacks der oralen flüssigen chinolon-zubereitungen mit ionenaustauscherharzen |
US6514492B1 (en) | 1999-07-14 | 2003-02-04 | Schering-Plough Veterinary Corporation | Taste masking of oral quinolone liquid preparations using ion exchange resins |
GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
US7067116B1 (en) * | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
US20020031490A1 (en) * | 2000-07-27 | 2002-03-14 | Bellamy Simon Andrew | Method for preparing resinates |
EP1429728A1 (en) * | 2001-08-29 | 2004-06-23 | SRL Technologies, Inc. | Sustained release preparations |
ATE396746T1 (de) * | 2002-01-18 | 2008-06-15 | Rohm & Haas | Verwendung eines resinats zur herstellung einer formulierung zur beendigung des rauchens |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
US20050142097A1 (en) * | 2003-12-29 | 2005-06-30 | Deepak Thassu | Multiple active drug resin conjugate |
WO2007001300A1 (en) * | 2005-06-28 | 2007-01-04 | Ucb, S.A. | Multiple active drug-resin conjugate |
US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
EP1926736A4 (en) * | 2005-09-21 | 2010-08-25 | Chong Kun Dang Pharm Corp | NEW RESINATE COMPLEX OF S-CLOPIDOGREL AND METHOD FOR THE PRODUCTION THEREOF |
EP2018160B1 (en) | 2006-03-16 | 2011-12-14 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
CN100411626C (zh) * | 2006-08-28 | 2008-08-20 | 浙江大学 | 缓释型碘补充剂的制备方法 |
US8287848B2 (en) | 2006-10-03 | 2012-10-16 | Tris Pharma Inc | Formulations containing an ionic mineral-ion exchange resin complex and uses thereof |
CN100450548C (zh) * | 2006-12-22 | 2009-01-14 | 江苏奥赛康药业有限公司 | 一种波拉克林树脂组合物的口腔贴片及其制备方法 |
MX2010003928A (es) * | 2007-10-11 | 2010-09-10 | Philip Morris Prod | Producto de tabaco sin humo. |
WO2009102830A1 (en) * | 2008-02-13 | 2009-08-20 | Eurand Inc | Orally disintegrating tablet compositions of ranitidine and methods of manufacture |
JP5560701B2 (ja) * | 2008-12-26 | 2014-07-30 | ライオン株式会社 | ラニチジン含有医薬固形製剤及びラニチジン担持粒子の製造方法 |
JP5412966B2 (ja) * | 2009-06-08 | 2014-02-12 | ライオン株式会社 | 粒状製剤 |
US8357398B2 (en) * | 2009-10-21 | 2013-01-22 | Alitair Pharmaceuticals Inc. | Benzonatate compositions and methods of use |
CN102198118B (zh) * | 2011-03-28 | 2012-08-29 | 于晓勇 | 一种治疗呕吐的口腔药物制剂及其制备方法 |
CN102138915A (zh) * | 2011-03-28 | 2011-08-03 | 于晓勇 | 一种口服药物制剂及其制备方法 |
BR112015003120B1 (pt) | 2012-08-15 | 2022-08-09 | Tris Pharma , Inc | Tablete mastigável de liberação estendida de metilfenidato e seu uso |
RU2761346C2 (ru) * | 2016-11-01 | 2021-12-07 | Джонсон энд Джонсон Консьюмер Инк. | Жидкая пероральная фармацевтическая лекарственная форма, содержащая антагонист h2-рецептора гистамина и антацид |
EP3784214A4 (en) | 2018-04-27 | 2022-01-19 | Johnson & Johnson Consumer Inc. | LIQUID ORAL PHARMACEUTICAL DOSAGE FORM |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR803638A (fr) * | 1935-06-21 | 1936-10-05 | Système de freinage pour portes coulissantes | |
US2828207A (en) * | 1955-11-14 | 1958-03-25 | Du Pont | Fortification of feed |
US2990332A (en) * | 1958-04-02 | 1961-06-27 | Wallace & Tiernan Inc | Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith |
US2970053A (en) * | 1958-10-28 | 1961-01-31 | Pfizer & Co C | Oleandomycin resin adsorbate |
US3138525A (en) * | 1961-06-16 | 1964-06-23 | Hoffmann La Roche | Castor wax-amprotropine-resin compositions |
US3949068A (en) * | 1964-02-20 | 1976-04-06 | University Of Alabama In Birmingham Medical And Educational Foundation | Pharmaceutical compositions |
GB1180233A (en) * | 1966-02-23 | 1970-02-04 | Jean Astruc | Modified Spiramycin |
US3624209A (en) * | 1966-12-28 | 1971-11-30 | Bristol Myers Co | Composition for treatment of gastro-intestinal disorders |
GB1218102A (en) * | 1968-03-15 | 1971-01-06 | Philips Nv | Improvements in medicaments comprising drug/ion-exchange resin compounds |
JPS5146154B2 (ko) * | 1972-05-11 | 1976-12-07 | ||
GB1462356A (en) * | 1973-07-10 | 1977-01-26 | Beecham Group Ltd | Pharmaceutical compositions |
JPS51125708A (en) * | 1974-07-23 | 1976-11-02 | Beecham Group Ltd | Production of betaalactam antibiotic complex |
GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
CY1306A (en) * | 1980-10-01 | 1985-12-06 | Glaxo Group Ltd | Aminoalkyl furan derivative |
IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
EP0077529B1 (de) * | 1981-10-16 | 1985-07-17 | Sanol Schwarz GmbH | Arzneimittelformulierung |
GB8313217D0 (en) * | 1983-05-13 | 1983-06-22 | Glaxo Group Ltd | Pharmaceutical compositions |
NZ215069A (en) * | 1985-03-01 | 1988-06-30 | Reckitt & Colmann Prod Ltd | Pharmaceutical composition with histamine h 2 -receptor antagonist |
US4788055A (en) * | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
JPS6369038A (ja) * | 1986-09-10 | 1988-03-29 | Canon Inc | 光カ−ド記録媒体 |
US4795641A (en) * | 1987-08-20 | 1989-01-03 | Eastman Kodak Company | Polymer blends having reverse phase morphology for controlled delivery of bioactive agents |
-
1989
- 1989-05-09 IL IL9024589A patent/IL90245A/en not_active IP Right Cessation
- 1989-05-10 PT PT90523A patent/PT90523B/pt not_active IP Right Cessation
- 1989-05-10 LU LU87515A patent/LU87515A1/fr unknown
- 1989-05-10 FR FR8906102A patent/FR2631232B1/fr not_active Expired - Fee Related
- 1989-05-10 US US07/349,999 patent/US5032393A/en not_active Expired - Fee Related
- 1989-05-10 CH CH1752/89A patent/CH679011A5/fr not_active IP Right Cessation
- 1989-05-10 DE DE3915347A patent/DE3915347C2/de not_active Expired - Fee Related
- 1989-05-10 HU HU892349A patent/HU204994B/hu not_active IP Right Cessation
- 1989-05-10 SE SE8901671A patent/SE508343C2/sv not_active IP Right Cessation
- 1989-05-10 GR GR890100314A patent/GR1000358B/el unknown
- 1989-05-10 PH PH38630A patent/PH27612A/en unknown
- 1989-05-10 CN CN89103232A patent/CN1027133C/zh not_active Expired - Fee Related
- 1989-05-10 BE BE8900501A patent/BE1002159A5/fr active
- 1989-05-10 YU YU97189A patent/YU47674B/sh unknown
- 1989-05-10 PL PL27937789A patent/PL279377A1/xx unknown
- 1989-05-10 GB GB8910706A patent/GB2218333B/en not_active Expired - Fee Related
- 1989-05-10 MX MX1598389A patent/MX173349B/es unknown
- 1989-05-10 NZ NZ229064A patent/NZ229064A/en unknown
- 1989-05-10 IT IT8947938A patent/IT1232831B/it active
- 1989-05-10 ES ES8901601A patent/ES2011573A6/es not_active Expired - Lifetime
- 1989-05-10 KR KR1019890006425A patent/KR890016968A/ko active IP Right Grant
- 1989-05-10 FI FI892248A patent/FI92060C/fi not_active IP Right Cessation
- 1989-05-10 RU SU894614142A patent/RU2033155C1/ru active
- 1989-05-10 JP JP1117167A patent/JP2944678B2/ja not_active Expired - Lifetime
- 1989-05-10 AU AU34617/89A patent/AU624613B2/en not_active Ceased
- 1989-05-10 AT AT0112089A patent/AT401614B/de not_active IP Right Cessation
- 1989-05-10 DK DK229489A patent/DK168934B1/da not_active IP Right Cessation
- 1989-05-10 IE IE152789A patent/IE60722B1/en not_active IP Right Cessation
- 1989-05-10 NO NO891906A patent/NO175131C/no unknown
- 1989-05-10 CA CA000599350A patent/CA1337272C/en not_active Expired - Fee Related
- 1989-05-11 NL NL8901188A patent/NL8901188A/nl active Search and Examination
- 1989-05-11 MY MYPI89000634A patent/MY104013A/en unknown
-
1994
- 1994-04-08 SG SG48194A patent/SG48194G/en unknown
- 1994-05-05 HK HK45094A patent/HK45094A/xx not_active IP Right Cessation
-
1995
- 1995-06-28 HU HU95P/P00512P patent/HU211592A9/hu unknown
- 1995-10-20 CY CY178195A patent/CY1781A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890016968A (ko) | 약제 흡착물 | |
EP0368682B1 (en) | Pharmaceutical ion exchange resin composition | |
US5629316A (en) | Stabilized solid pharmaceutical preparation and method of producing the same | |
US8835500B2 (en) | Pharmaceutical formulations of amyloid inhibiting compounds | |
KR890000082A (ko) | 서방성 제제 및 그의 제조방법 | |
KR900015737A (ko) | 배합물 | |
AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
KR880004804A (ko) | 분무건조 아세트 아미노펜 | |
ZA894728B (en) | A new pharmaceutical formulation as well as a process for its preparation | |
KR880004807A (ko) | 수산화알루미늄을 함유하는 이부프로펜 조성물 | |
CA1336323C (en) | Process for the preparation of anti-inflammatory pharmaceutical agents with an ibuprofen base, with elimination, in solution, of the bitter taste, burning of the throat and intestinal toxicity | |
US4980375A (en) | Onset-hastened/enhanced antipyretic response | |
US5739165A (en) | Stabilized solid pharmaceutical preparation and method of producing the same | |
d'Arcy et al. | Drug interactions in the gut involving metal ions | |
US3885035A (en) | Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines | |
WO1996022068A3 (en) | Methods and pharmaceutical compositions employing desmethylselegiline | |
JPH0680577A (ja) | 鎮咳剤 | |
EP0068365A1 (en) | Antiviral alpha, alpha-dialkyl adamantylethylamines | |
US3070508A (en) | Method for rendering nicotinamide palatable | |
Rodríguez | Antagonism of tremorine-induced tremor by serotoninergic agents in mice. Interactions with levodopa. | |
CZ79593A3 (en) | Antitussive preparation | |
US3919424A (en) | Bronchodilator process and composition | |
US3342685A (en) | Vitamin-cation exchange resin therapy and method of eliminating drug odor | |
GB2064958A (en) | Medicaments containing aspirin | |
JPH0141606B2 (ko) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
NORF | Unpaid initial registration fee |